Carvedilol Versus Endoscopic Band Ligation for Primary Prophylaxis of Oesophageal Variceal Bleeding

Last updated: August 1, 2020
Sponsor: Sherief Abd-Elsalam
Overall Status: Active - Recruiting

Phase

2/3

Condition

Esophageal Disorders

Treatment

N/A

Clinical Study ID

NCT04499898
nabeela protocol
  • Ages > 18
  • All Genders

Study Summary

Carvedilol versus endoscopic band ligation for primary prophylaxis of oesophageal variceal bleeding in cirrhotic patients with arterial hypertension

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • • Aged >18 years

  • Cirrhotic patients with arterial hypertension

  • Endoscopic evidence of medium/large-sized esophageal varices

Exclusion

Exclusion Criteria:

  • • History of variceal bleeding or previous primary prevention of varices.

  • Portal vein thrombosis or previous porto-systemic shunts as TIPS.

  • Patients on drugs affecting portal pressure (beta blockers, nitrates).

  • Advanced cardiovascular disease including acute myocardial infarction,atrio-ventricular block, congestive heart failure, chronic peripheral ischemia,severe bradycardia.

  • Patients with severe respiratory diseases (COPD, bronchial asthma).

  • Uncontrolled diabetes mellitus

  • Renal impairment

  • Hepatocellular carcinoma

  • Allergy to carvedilol

  • Pregnancy or lactation

Study Design

Total Participants: 306
Study Start date:
October 01, 2018
Estimated Completion Date:
December 10, 2030

Study Description

A Randomized controlled trial of carvedilol versus endoscopic band ligation for primary prophylaxis of oesophageal variceal bleeding in cirrhotic patients with arterial hypertension

Connect with a study center

  • Sherief Abd-Elsalam

    Tanta,
    Egypt

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.